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STUDY PROTOCOL Open Access
Study protocol: ASCRIBED: the impact of
Acute SystematiC inflammation upon
cerebRospinal fluId and blood BiomarkErs
of brain inflammation and injury in
dementia: a study in acute hip fracture
patients
Nick Leavey1, Simon P. Hammond2, Lee Shepstone3, Jane Cross4, Henrik Zetterberg5,6,7,8, Colm Cunningham9,
Alasdair MacLullich10, Leiv Otto Watne11, Anne Marie Minihane12, Clive Ballard13, Anne-Brita Knapskog14,
Roanna Hall15, Gregory Howard1, Matt Hammond1 and Chris Fox16*
Abstract
Background: Hip fracture represents a substantial acute inflammatory trauma, which may constitute a significant
insult to the degenerating brain. Research suggests that an injury of this kind can affect memory and thinking in
the future but it is unclear whether, and how, inflammatory trauma injures the brain. The impact of Acute
SystematiC inflammation upon cerebRospinal fluId and blood BiomarkErs of brain inflammation and injury in
Dementia: a study in acute hip fracture patients (ASCRIBED) explores this relationship, to understand the effect of
inflammation on the progression of dementia.
Methods: This protocol describes a multi-centre sample collection observational study. The study utilises the
unique opportunity provided by hip fracture operations undertaken via spinal anaesthesia to collect cerebrospinal
fluid (CSF) and blood, to investigate the impact of acute brain inflammation caused by hip fracture on the
exacerbation of dementia. We will recruit 200 hip fracture patients with a diagnosis or evidence of dementia; and
200 hip fracture patients without dementia. We will also recruit ‘Suitable informants’, individuals in regular contact
with the patient, to provide further proxy evidence of a patient’s potential cognitive decline. We will compare these
400 samples with existing CSF and blood samples from a cohort of dementia patients who had not experienced a
systemic inflammatory response due to injury. This will provide a comparison between patients with and without
dementia who are suffering a systemic inflammatory response; with stable patients living with dementia.
(Continued on next page)
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: Chris.Fox@uea.ac.uk
16Department of Psychological Sciences, Norwich Medical School, Faculty of
Medicine and Health Sciences, University of East Anglia, Norwich Research
Park, Norwich NR4 7TJ, England
Full list of author information is available at the end of the article
Leavey et al. BMC Neurology          (2019) 19:223 
https://doi.org/10.1186/s12883-019-1447-7
(Continued from previous page)
Discussion: We will test the hypothesis that hip fracture patients living with dementia show elevated markers of
brain inflammation, as well as neuronal injury and Alzheimer-related plaque pathology, in comparison to (1) stable
patients living with dementia and (2) hip fracture patients without dementia, as measured by biomarkers in CSF
and blood. The findings will address the hypothesis that systemic inflammatory events can exacerbate underlying
dementia and inform the search for new treatments targeting inflammation in dementia.
Trial registration: ISRCTN43803769. Registered 11 May 2017.
Keywords: Dementia, Hip fracture, Inflammation, Cerebrospinal fluid
Background
Inflammation is a beneficial physiological response to
tissue damage or infection. However, when inflammation
is extensive or not fully resolved, this can damage
healthy tissues and disrupt normal cellular function. Hip
fracture represents a substantial systemic inflammatory
trauma, common in older people, which may constitute
a significant insult to the degenerating brain and there-
fore contribute to the progression or even the onset of
dementia. Hip fracture in older people has therefore
been linked with poor cognitive outcomes, including de-
lirium in the short-term, increased dependency and cog-
nitive decline, especially in patients with dementia [1–3].
The association and pathological role of inflammation
in dementia has been extensively described [4]. Studies
have shown that microglial cells (the brain’s main
macrophage population) are activated in the vicinity of
amyloid plaques in dementia [5]. More recent studies
suggest that altered macrophage function may contrib-
ute to dementia [6]. Animal studies have shown that
microglial activation is a consistent feature in dementia
and there is evidence that inflammation contributes to
the disease process [7, 8] but the physiological and mo-
lecular basis for this remains unclear.
Current evidence from human epidemiological studies,
human data from blood, cerebrospinal fluid and imaging,
and animal models, have established that alongside
chronic localised inflammation resulting from and con-
tributing to neurodegenerative diseases such as demen-
tia, there is also neurodegeneration induced by acute
inflammatory processes [9] and changes in amyloid pro-
cessing [10]. Understanding this alternative route to
neurodegeneration is becoming increasingly important
as the population ages. This is because acute systemic
inflammatory episodes, such as infection and inflamma-
tory trauma, are common in older people with some
evidence of this having both acute [11] and lasting [12]
impacts on cognitive function. Therefore, it is plausible
that such episodes are an important cause of decline in
people living with dementia, which is clinically almost
completely unaddressed.
With rapid advances in identifying and measuring/
testing cerebrospinal fluid (CSF) and blood biomarkers
of brain inflammation, brain injury and Alzheimer-asso-
ciated amyloid β (Aβ) plaque pathology, there is the op-
portunity to study this in humans.
Previous studies in older people with acute systemic
inflammation have been limited by small sample sizes,
the lack of adequate control groups and, in particular,
have not assessed the impact of inflammation on re-
cently emerging biomarkers of new brain injury [13].
One of the other difficulties encountered by research
in this area is that hip fracture is an emergency and
studies cannot directly collect pre-fracture data. How-
ever, well-validated methods for the assessment of pre-
fracture cognitive ability are available. The Informant
Questionnaire for Cognitive Decline in the Elderly
(IQCODE [14] is one example widely-used clinically and
for research purposes.
In the United Kingdom (UK) a significant proportion
of hip fracture patients undergo surgery within spinal
anaesthesia [15]. This routine clinical procedure involves
inserting a needle into the patient’s spinal space (sub-
arachnoid space) and injecting anaesthetic into the CSF.
In this way, CSF can be collected just before the initi-
ation of anaesthesia, using the same needle that will be
used to administer the anaesthetic agent. This means
that older patients undergoing emergency hip fracture
repair surgery are a suitable group in which to measure
systemic inflammation, brain inflammation and CSF
markers of brain injury.
The impact of Acute SystematiC inflammation upon
cerebRospinal fluId and blood BiomarkErs of brain in-
flammation and injury in Dementia: a study in acute hip
fracture patients (ASCRIBED) will use the opportunity
provided by hip fracture operations undertaken via
spinal anaesthesia to investigate the impact of acute
systematic inflammation upon CSF and blood bio-
markers of brain inflammation and neuronal injury and
on the exacerbation of dementia. We will collect samples
from patients with and without dementia who are suffer-
ing a systematic inflammatory response (the ASCRIBED
cohort). We will compare ASCRIBED’s ‘unstable’ groups
(termed as to refer to the inflammatory response) with
an existing cohort of patients living with dementia who
have not experienced a systemic inflammatory response
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from an injury (henceforth known as the ‘Oslo’ co-
hort). The Oslo cohort will therefore provide ‘stable’
comparators. The study will shed light on the ability
of acute inflammatory trauma to produce new brain
injury in a vulnerable older population. The findings
will then inform the search for new treatments targeting
inflammation in dementia.
Methods
Aims and objectives
In order to have specific measures informing on the se-
verity of prevalent systemic inflammation at the time of
lumbar puncture (i.e., the time of CSF collection), matched
to those inflammatory mediators occurring in the CSF, we
will quantify inflammatory mediators (including but not
limited to IL-1β, TNF-α, IL-6) in both peripheral blood
and in CSF. In order to assess brain injury we will measure
CSF markers of brain injury (including but not limited to
total and phosphorylated tau [T-tau and P-tau, re-
spectively], neurofilament light [NfL] and neurogra-
nin). Brain injury markers will also be measured in
blood. Aβ42/40 ratio in CSF and plasma, measured
using immunoassays (Meso Scale Discovery and Simoa
methods, respectively), will be used as a biomarker of
cerebral Aβ pathology. We will also collect an add-
itional 2.5 ml of whole blood from patients. Several
studies have recently been published using PAXgene
blood collection tubes for later transcriptomic ana-
lysis. Our intention is to place ourselves in the pos-
ition to examine blood signatures that associate with,
and may be predictive of, particular CSF and clinical
outcomes in our patients for later analysis. Banking
these samples will enable further in-depth analysis and
is in accordance with the trial ethical approval and
consent process.
Primary objective
To determine whether hip fracture patients living with de-
mentia show elevated markers of brain inflammation in
comparison to (1) stable patients living with dementia and
(2) hip fracture patients without dementia, as measured by
biomarkers in CSF. CSF inflammation will be measured
by TNF-α, IL-1RA, IL-1β, IL-6 and brain injury and
biomarkers will be measured by NfL, neurogranin, T-tau,
synaptotagmin and SNAP-25.
Secondary objectives
To determine whether the magnitude of the brain
inflammatory response predicts the quantity of spe-
cific brain injury markers measured in the CSF.
Magnitude of the brain injury will be assessed via
brain injury markers T-tau, P-tau, NfL, neurogranin,
synaptotagmin and SNAP-25 in CSF. We will also
examine if patients who are Aβ-positive at baseline
are more or less likely to have dementia or develop
dementia at follow-up. We will also look for interac-
tions of Aβ positivity with the other biomarkers in
regards to clinical outcome.
Design
This observational study will recruit patients with prox-
imal hip fractures who undergo surgery via spinal anaes-
thesia. The majority of patients admitted with a hip
fracture are cognitively vulnerable. This may be a pre-frac-
ture state or an acute reaction to the hip fracture. Clinic-
ally, patients arriving in acute settings do not always arrive
with a confirmed dementia diagnosis. However, in the UK,
it is routine clinical practice to cognitively screen hip frac-
ture patients over the age of 60 years. In England, the Ab-
breviated Mental Test (AMT) is commonly used [16]. In
Scotland, the 4AT is used as best standard practice [17].
Because evidence highlights that the mapping of a pa-
tient’s score on the 4AT on to the AMTS is possible [18,
19], we will use routinely available clinical data to pre-op-
eratively assign recruited patients to one of two groups, ei-
ther ‘confused’ or ‘non-confused’. In this way, we will
employ the term confusion to reflect the real-world com-
plexity of the acute hospital environment and initially as-
sign patients accordingly, based on these existing
cognitive clinical screening practices (see Fig. 1). Specific-
ally, Group 1 patients will have a pre-op AMT score of ≤8
(England), or a 4AT score of > 1 (Scotland); and Group 2
patients will have a pre-op AMT score of > 9 (England) or
4AT score of 0 (Scotland).
Whilst these are indicative of the possibility that the
patient may have some form of dementia/cognitive im-
pairment, it is often not possible to obtain confirmative
evidence until at least 1-month post-op. Using the AMT
or 4AT scores allows us to allocate patients to a group
at the recruitment stage. However, we will also take into
account any subsequent evidence of dementia in the
analysis, by gaining permission/consent to access a pa-
tient’s notes and/or where possible, a consented suitable
informant (someone who has contact with the patient
at least once a month face-to-face or via telephone) via
the Informant Questionnaire for Cognitive Decline in
the Elderly (IQCODE). This will inform what final
group cohort the patient is then allocated to. In the
absence of a formal documented diagnosis of dementia
and in accordance with previous research [20, 21], pa-
tients with an associated suitable informant IQCODE
score of 3.31 and above will be assessed as having suffi-
cient evidence of dementia to be allocated to the corre-
sponding group cohort.
Setting
The study setting is acute trauma wards in hospitals
across England and Scotland to which individuals
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suffering Neck of Femur (NoF) fractures are admitted.
In all instances, the investigator(s) will be able to
demonstrate a potential for recruiting the required
number of suitable participants within the agreed re-
cruitment period (i.e. the investigator(s) regularly
treat(s) the target population). For these reasons, the
study management team will target NHS Hospitals
with large annual admission rates of NOF fractures
with sufficiently high percentages of operations being
undertaken via spinal anaesthesia. This information
was readily available through the National Hip Frac-
ture Database (NHFD) for all NHS Trusts in England
[16]. In Scotland, we targeted large centres known to
the study group and with existing expertise in collect-
ing CSF for research purposes.
Participants
We will be collecting samples and data from two
groups of patient participants (n = 200 in each
group). Due to the cognitively vulnerable nature of
the patient population and feasibility learning in relation to
dementia diagnosis rates of our target population [22], we
will seek proxy information about pre-fracture cognition to
inform grouping allocation for analysis. Consequently, we
will also seek written consent from “suitable informants” as
defined by the inclusion criteria below, to complete the In-
formant Questionnaire for Cognitive Decline in the Elderly
(IQCODE). The recruitment of a suitable informant for
each patient is desirable, but not essential. The eligibility
criteria for patient participants and suitable informant par-
ticipants are as follows:
Patient inclusion criteria:
Group 1: ‘Confused’ hip fracture patients
Inclusion Criteria:
1) Patient must have had a confirmed proximal hip
fracture requiring an operation and be aged 60 or
older at the time of operation;
2) Patient has a pre-operative Abbreviated Mental
Test Score (AMTS) of 8 or below; or 4AT score of
1 or above;
3) Patient must be undergoing spinal anaesthesia.
Exclusion criteria:
1) Decision taken not to have hip surgery;
2) Patient has head trauma with bleeding as indicated
by a CT scan;
3) Patient has confirmed diagnosis of Parkinson’s disease;
4) Patient not expected to survive beyond 4 weeks;
5) Patient’s fall and subsequent hip fracture caused by
acute Stroke, indicated by CT and/or MRI scan
and/or clinical examination;
6) Patient already enrolled in a Clinical Trial of an
Investigational Medicinal Product (CTIMP).
Group 2: ‘Non-confused’ hip fracture patients
Inclusion Criteria:
1) Patient must have had a confirmed proximal hip
fracture requiring an operation and be aged 60 or
older at the time of operation;
Fig. 1 Study Diagram and Group Allocation of Patients
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2) Patient has a pre-operative AMTS of 9 or above; or
4AT score of 0;
3) Patient must be undergoing spinal anaesthesia.
Exclusion criteria:
1) Decision taken not to have hip surgery;
2) Patient has head trauma with bleeding as indicated
by a CT scan.
3) Patient has confirmed diagnosis of Parkinson’s disease;
4) Patient not expected to survive beyond 4 weeks;
5) Patient’s fall and subsequent hip fracture caused by
acute Stroke, indicated by CT and/or MRI scan
and/or clinical examination;
6) Patient already enrolled in a Clinical Trial of an
Investigational Medicinal Product (CTIMP).
Suitable informants
Inclusion Criteria:
1) Individual has a minimum of once a month
face-to-face or telephone contact with the
patient;
2) Individual is able and consents to complete the
IQCODE.
Exclusion Criteria:
1) Individual under 16 years of age.
Recruitment and consent procedures
A three-phase recruitment process has been guided by
conversations with clinical and academic collaborators
and previous experience recruiting from this patient
group [22].
1.) Research Nurses will collaborate with relevant
clinical staff (including but not exclusively the
study ward Trauma Co-ordinators and key
Emergency Department colleagues) to identify all
new hip fracture admissions and screen for pre-
recruitment eligibility;
2.) Each patient (and where possible their potential
suitable informant) will be approached by a
Research Nurse who will provide information about
the study as soon as clinically appropriate. During
this initial approach, the Research Nurse will also
assess the mental capacity of the patient;
3.) The Research Nurse will approach the patient
(where possible) and the identified suitable
informant to obtain full written informed consent.
In cases where written consent is not possible,
ethical approval allows for witnessed verbal consent.
In English trial sites, in line with Principle 1 of the
Mental Capacity Act 2005 [23], a potential patient par-
ticipant will be assumed to have capacity until it is estab-
lished otherwise. When this is the case and all practical
steps to help them to engage in the decision making
process have been tried (Principle 2 of Mental Capacity
Act 2005), the site trial team will seek a personal con-
sultee. This person will be someone who is engaged in
care for the participant (not professionally or for pay-
ment) or is interested in his/her welfare and is prepared
to be consulted. This may be a family member, carer or
close friend, or attorney acting under Lasting Power of
Attorney. This person can also act as a suitable inform-
ant if they fulfil the inclusion criteria.
If a potential personal consultee is not available or de-
clines to take part, alternatively a nominated consultee
will be sought. This will be a person independent of the
research study and who is willing to be consulted about
the participation of a person who lacks capacity where
reasonable steps have been taken to identify a personal
consultee. This may be someone who knows the patient
in a professional capacity e.g. social worker, ward staff
member, paid carer or GP, provided they have no con-
nection to the research study.
In Scottish sites, in line with the Adults with Incap-
acity Act 2000 [24], where a potential patient participant
is assessed not to have capacity, a welfare guardian, wel-
fare attorney or nearest relative will be sought and asked
to consent in relation to participation in research (this
person will be henceforth known as a legal representa-
tive). This procedure will be undertaken once an assess-
ment of capacity has been made in relation to the
specific decision regarding the research participation,
any barriers to participating in the consent process have
been removed and the local research worker feels the in-
dividual cannot retain information long enough to use it
in order to arrive at a decision.
Legal representatives may be involved in conversations
regarding the consenting process. However, they will be
asked to differentiate between expressions of their own
views and reporting the known values and/or views of
the potential patient participant. If the potential partici-
pant is unable to consent for himself or herself, then
consent will be sought on their behalf from a suitable
legal representative.
In cases where gaining full written consent is not pos-
sible research workers may take witnessed verbal con-
sent (patients or legal representatives) or agreement
(personal consultees). For patients this may be needed
due to an inability to write because of injury. With per-
sonal consultees or legal representatives this may be due
to distance therefore study information may be conveyed
over the phone with relevant forms sent via email if
appropriate. Where witnessed verbal agreement/consent
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is taken, full written agreement/consent will be sought
where practically possible. A record of all witnessed ver-
bal consent will be added to the patient’s notes.
In both England and Scotland, if during a follow-up
assessment the patient is assessed by a local research
worker to have regained capacity (a possibility in the
case of some cognitive impairments such as delirium);
he/she will be approached about continuing to partici-
pate in the study and asked to give informed consent.
Should they choose to withdraw from the study at this
point, the study team reserve the right to retain any data
and samples collected up until the point of the patient’s
withdrawal. This will be clearly stated in the patient and
Consultee (English sites)/Legal Representative (Scottish
Sites) Information Sheets.
This three-phase process will be closely monitored to
identify trends that might be leading to over or under
recruitment from specific groups. For example, if sites
are consenting purely via personal consultees (England)
or legal representatives (Scotland), monitoring will en-
able corrective actions and provide information to miti-
gate these recruitment trends.
Recruiting patients with fluctuating and/or reduced
capacity in England and Scotland
The aims of this study are incompatible with only enrol-
ling patients with minimal or mild confusion. It is im-
portant to ensure findings are broadly applicable to
those patients with a pre-existing diagnosis or evidence
of dementia. Participants who lack capacity to give in-
formed consent must therefore be included. In this situ-
ation, the patient’s agreement to participate will still be
obtained to their best level of understanding (in line
with legislative frameworks in England [23] and Scotland
[24]). Where patients in England are assessed as lacking
capacity to make a decision regarding their initial or
continued involvement with the study, we will seek a
personal or nominated consultee agreements [25]. In
Scottish study sites where a patient is assessed not to
have capacity, a legal representative will be sought and
asked to consent in relation to the patient’s participation
in the research [26].
Approaching patients post-operatively
Where possible, the patient will be approached at a clin-
ically suitable time approximately 48 h (± 4 h) following
their operation. However, in order to facilitate patient
recruitment and because successful collection of a suffi-
cient number of pre-operative CSF samples is the prior-
ity for this study, sites are encouraged to screen and
recruit patients from Monday-Friday. This is on the un-
derstanding that should a patient be consented on a
Thursday/Friday, it may not be possible to complete the
48-h follow-up due to insufficient Research Nurse cover
during weekends.
During the 48-h follow-up point, we will aim to collect
the post-operative blood sample and Mini-Mental State
Examination - 2nd Edition, Short-Form version (MMSE~
2: SV) data. As appropriate, the research nurse will remind
the patient of the study, reassess capacity (as required)
and complete pre-consented study related procedures.
In English sites, for patients who previously provided
informed consent on their own behalf but are as
assessed as having since lost capacity at this follow-up
point, we will seek a personal or nominated consultee
agreements [23]. As part of the patient consent form
for Trusts based in England, patients will be asked to
provide contact details for someone who may be will-
ing to act as a personal consultee in the event that the
patient loses capacity. Patients will also be asked to
sign an advanced statement of intent, stating that
should they be assessed as having lost capacity post-
operatively, they would still like to be involved in the
study should a consultee be available. A more detailed
overview of the recruitment process is shown in Fig. 2:
Recruitment overview.
Data collection (Table 1)
Day of operation
The research nurse and/or anaesthetist at the time of
the hip fracture operation will be responsible for collect-
ing 18.5 ml of whole blood (1 × 6.0 ml of blood ethylene-
diaminetetraacetic acid (EDTA) tube, 2 × 5.0 ml serum
tube and 1 × 2.5 ml PAXgene tube) and the collection of
2.0–6.0 ml of CSF (anaesthetist only).
Sites will be instructed to centrifuge CSF samples
within 1 h of sample collection at 2000G for 10 min. If
CSF samples are not centrifuged within a maximum of
2 h of collection, site teams will be informed to destroy
the samples and alert the study management team ac-
cordingly. Blood serum samples will be centrifuged at
2000G for 15 min, within 1 h of collection. If any blood
serum samples are not centrifuged within 3 h of collec-
tion, they must be rejected and destroyed; and the study
management team notified accordingly. The EDTA and
PAXgene samples will not require centrifugation and
sites are instructed to leave these to rest at room
temperature for 2 h, following inversion.
Once processed and ready for storage, the CSF,
EDTA and blood serum samples will be aliquotted into
0.5 ml samples within 1.5 ml capacity Cryotubes, and
stored in a specific patient Cryobox. Both the Cryobox
and all of the individual Cryotubes used for patient
sample storage are labelled with the patient’s unique
study identifier number and colour coded to match the
sample type being stored. PAXgene samples are also
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labelled accordingly but remain stored in their initial
vacutainers, inside the corresponding patient’s Cryobox.
The Cryobox will then be stored in a -80° Celsius
freezer at the local research site. All of the sample
collection, processing and storage times for each
patient will be recorded within the study’s electronic
database for monitoring purposes.
Once a site has successfully recruited and collected
samples for 10 patients, the study management team will
arrange for a courier to collect and deposit the samples
Fig. 2 Recruitment Overview and Participant Flow
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at the Norwich Biorepository for long-term storage, until
the final sample analysis is ready to be started. All sam-
ple transfers will be completed on a same day delivery
basis, using dry ice to maintain sample cooling. Once at
the Norwich Biorepository, samples will be monitored
against the electronic database records and sample
transfer log, for completeness and accuracy. Samples will
then be deposited in a -80° Celsius freezer within the
Norwich Biorepository. Any discrepancies will be
followed up with the local research team and recorded
in the electronic database accordingly.
Spinal anaesthesia will be performed according to local
trust procedures. After placement of the needle to de-
liver the spinal anaesthetic, and prior to administration
of the anaesthetic agent, a sample of between 2 and 6ml
of CSF will be collected. Patients unable to provide a
sufficient CSF sample will be withdrawn from the study
and any prior samples collected destroyed according to
Local Trust Policy.
During collection of the CSF, the patient will be moni-
tored. Should the patient’s discomfort become too great,
the anaesthetist will stop collecting the CSF. Headaches
(‘post-dural-puncture headache’ or ‘PDPH’) are a com-
mon side effect of spinal anaesthesia and typically occur
within two to 3 days following the procedure. After tak-
ing advice from anaesthetists, it was identified that the
risk of patients experiencing a PDPH may be slightly
higher for patients taking part in this study because of
the additional CSF withdrawn. The incidence of PDPH’s
will therefore be monitored as part of routine care using
standard local procedures. Any PDPH observed by the
clinical team will be assessed for severity and reported as
an adverse event. The incidence rates of PDPH’s will be
monitored and review by the Data Monitoring and Eth-
ics Committee (DMEC) and Study Steering Committee
(SSC). However, the risk is expected to be negligible.
Post-op 48 h (± 4 h)
2 × 5.0 ml blood (serum tube) will be collected from the
patient. Every effort will be made to collect post-opera-
tive bloods within this time window, but this may not al-
ways be possible. Therefore, research nurses will collect
the MMSE~ 2: SV data and bloods at the next earliest
opportunity but not beyond 60 h post-op. The time
point at which these samples and data are collected will
be noted and fed into the analysis. Sites consistently col-
lecting samples outside the 48 (± 4 h) window will be
reviewed by the Study Management Group (SMG) who
will decide if they should be withdrawn. For patients
recruited on a Thursday or Friday, it is accepted that this
follow-up may not be possible due to insufficient Re-
search Nurses across weekends.
Post-op 1-month (± 5 days)
The 1-month post-op period will provide clinical teams
with an opportunity to contact the patient’s General
Practitioner (GP) and review their case notes to assess if
the patient has a pre-existing documented diagnosis of
dementia, as well as record some additional clinical mea-
sures and test results. If the patient has an eligible suit-
able informant, clinical teams will also use this time to
complete IQCODE assessment if they have not already
done so.
Sample size
We will recruit 200 patients with dementia and hip frac-
ture; and 200 patients without dementia but who have
experienced a hip fracture. This sample size is pragmatic-
ally based upon what would appear to be achievable in the
time available and with consideration of likely statistical
power. Without adjustment, a sample size of 200 subjects
per group will provide statistical power of 90% to detect a
mean between group mean differences of 0.33 standard
Table 1 Sample and data collection schedule
Timepoint Admission/Pre-Op
Period
Day of Operation Post-Op Period
Day 0 48 (± 4 hours) post-op Time 1 (1 month ± 5 days)
Consent/ Agreement X Xa
AMT and/or 4AT X Xb
Collection of blood EDTA sample (6 ml) X
Collection of blood serum clotted sample (10 ml) X Xb
Collection of Cerebrospinal fluid (CSF) sample (≥ 2.0 ml) X
MMSE~ 2: SV Xb
IQCODE (To be completed by the suitable informant) Xc
Evidence of dementia from patient’s medical/GP records Xc
Medication information Xc
Collection of blood PAXgene RNA sample (2.5 ml) X
aTaken if patient’s capacity status has changed from pre-operative time period (Eng. only);
bShould the time window be unworkable, research nurses will collect MMSE~ 2: SV data and bloods at the next earliest opportunity but not beyond 60 h post-op;
cCan be gained at any point before the 1-month (± 5 days) time period elapses
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deviations in any outcome variable using a two-sided sig-
nificance level of 5%. Assuming confounding variables en-
tered into a General Linear Model ‘explain’ no more than
25% of the total variation (i.e. the co-efficient of
determination, R2, is less than 0.25), then this sample size
should provide 90%. Power to detect an ‘adjusted’ mean
difference of around 0.37 residual standard deviations
[27]. In either case, this would be deemed a relatively
small effect to be detected with high probability.
Data will be collected initially from two different groups:
Group 1: Pre-operative acute hip fracture patients with
confusion;
Group 2: Pre-operative acute hip fracture patients
without confusion.
In respect of Group 1 (those with confusion), the AMT
(England) and 4AT (Scotland) score indicate that a patient
may be living with dementia. However, this may not be
confirmed until 1-month post-op when reviewing the pa-
tient’s case notes, contacting their GP or reviewing their
relevant Suitable Informant’s IQCODE Scores. Based on
prior research, we anticipate that up to 50% of patients
who have an AMT score of 8 or less (England) or 4AT
score of 1 or above (Scotland) will have dementia (diag-
nosed or undiagnosed/vectored) [22]. Therefore, up to
400 may need to be recruited to this group. Recruitment
will be monitored and stopped for Group 1 as soon as we
receive 200 patients with confirmed dementia required for
the study.
We will also collect data from patients without confu-
sion (Group 2), who are unlikely to be confirmed with
dementia at 1-month post-op. These patients will be in-
cluded in the non-dementia group. Again, recruitment
will be monitored and stopped from this group once 200
non-dementia patients have been included. The number
required from this group will be dependent upon the
non-dementia confirmation rate for this group.
There will be a number of patients from Group 1 (Pre-
operative acute hip fracture patients with confusion) for
whom we cannot find evidence of dementia at 1-month
post-op. The samples and data from this (confused, non-
dementia) group will be deposited into a biobank at the
Norwich Biorepository, for use in future research studies.
In cases where patients were initially in Group 2 (Pre-
operative acute hip fracture patients without confusion)
but where evidence of dementia is available at 1month
post-op, we will reallocate these patients to the dementia
patient group.
Comparable data will also be provided from a third group
(Oslo Cohort) of 200 ‘stable’ patients living with a con-
firmed dementia diagnosis, taken from existing memory
clinic data (Norwegian Registry of Persons with Cognitive
Symptoms (NorCog) (Reference: S-08143a and 2017/371).
Samples for this group are already available, as lumbar
puncture is part of the diagnostic workup of patients in-
cluded in the Norcog registry (Reference: S-08143a). These
samples were analysed in 2017 at Sahlgrenska for the fol-
lowing: Aβ38, Aβ40, Aβ42, 10xAb42/Ab40, YKL-40, IL-1β,
IL-6, IL-8, TNF-α, G36-NG2. The respective regional com-
mittee responsible have already provided permission
to compare these results with those gathered in the
present study.
Thus, we shall assemble data from 3 groups (hip frac-
ture and dementia, hip fracture and non-dementia,
stable and dementia), each with an expected 200 sub-
jects. Please (see Fig. 1: Study diagram and group alloca-
tion of patients).
Analysis
All analyses will be conducted according to a detailed
Statistical Analysis Plan (SAP), agreed by the Study
Management Group (SMG) prior to analysis. A sum-
mary of the main analyses are given below however:
Primary hypothesis
We will address the primary hypothesis, that systemic
inflammation arising from hip fracture leads to an acute
brain injury, by comparing the level of inflammatory and
neuronal injury CSF and blood markers between the
three groups defined above. Accordingly, we predict
raised inflammatory and injury markers for the con-
firmed dementia-hip fracture group compared to the
medically stable dementia group (Oslo cohort) and com-
pared to the non-dementia hip fracture group.
Each of the markers will be compared across groups
using a general linear model with the marker as the
dependent variable (i.e. a separate model for each bio-
marker). The initial model will simply include group as
an explanatory factor. A further model will then be con-
structed, including potential confounding variables, such
as age, to provide an adjusted between group mean dif-
ference (comparing fracture patients with dementia to
fracture patients without and fracture patients with
dementia to stable dementia patients), together with 95%
confidence intervals and significance test. In the event of
the residuals for these models not appearing normally
distributed, an appropriate transformation will be ap-
plied, such as a logarithmic transformation. We also pre-
dict that patients with dementia will have significantly
worse cognitive and functional informant-based scores.
A similar analysis will be conducted with cognitive and
functional scores as the dependent variable.
Secondary hypothesis
The secondary hypothesis is that the magnitude of the
brain inflammatory response will predict the quantity of
specific brain injury markers (phospho-tau, NfL,
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neurogranin, synaptotagmin, SNAP-25) measured in the
CSF. The strength of inter-relationship between the in-
flammatory and injury markers outlined will be examined
using correlation coefficients. These will also be adjusted
for potential confounding factors using partial correlation
coefficients.
Analysis of the samples will take place at UEA, Trinity
College Dublin and the University of Gothenburg.
Should additional information become available during
the course of the study, we will ensure that we use
the most appropriate analysis available to answer the
research questions.
 CSF will be analysed for a number of inflammatory
and neuronal injury markers. These include, but are
not limited to: TNF-α, IL-1RA, IL-1β, IL-6,
sTREM2, YKL-40, T-tau, P-tau, Aβ38, Aβ40, Aβ42,
neurogranin, synaptotagmin and SNAP-25;
 Blood collected pre-operatively and at 48 h (± 4 h)
will be analysed for TNF-α, IL 1RA, IL-1β, IL-6,
T-tau and NfL;
 Blood collected pre-operatively will also be
genotyped for the APOE ε2/ε3/ε4 polymorphism at
UEA;
 PAXgene blood for later transcriptomic analysis
looking for blood signatures that associate with, and
may be predictive of, particular CSF and clinical
outcomes in our patients.
Discussion
Despite significant investment, disease-modifying treat-
ments for dementia are still absent and there has been
no significant treatment breakthrough for 15–20 years
[28]. Inflammation is a vital part of the immune system’s
response to injury and infection which may become
harmful if exaggerated or unresolved. There is now
growing evidence that harmful inflammation in the brain
is aetiological and contributed to the pathophysiology of
dementia [29].
Recent research highlights acute illnesses or injuries
that cause inflammation throughout the body, such as
infection, trauma and surgery, can accelerate the
speed of decline in dementia [30, 31]. For example,
an infection in a hospitalised older person with de-
mentia is linked to a higher long-term worsening of
that person’s symptoms. The underlying mechanisms
linking inflammation, cognition and dementia pro-
gression remain greatly under-researched, with almost
no studies in humans. This lack of research impacts
on the search for new treatments targeting inflamma-
tion in dementia.
Thus this study will develop understandings of the role
of inflammatory response in dementia and support de-
veloping pharmaceutical interventions. Additionally it
will inform ways to predict deterioration in dementia.
Exploration of new potential disease pathways remains
essential for finding new therapeutic targets.
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